[1] L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet‐Tieulent, A.J.C.a.c.j.f.c. Jemal, Global cancer statistics, 2012, 65(2) (2015)
87-108.
[2] F.D. Moghaddam, S. Hamedi, M. Dezfulian, Anti-tumor effect of C-phycocyanin from Anabaena sp. ISC55 in inbred BALB/c mice injected with 4T1 breast cancer cell, Comparative Clinical Pathology 25(5) (2016) 947-952.
[3] M.R. Sarfjoo, A. Shad, M. Hassanpour, R.S. Varma, An Overview on New Anticancer Drugs Approved by Food and Drug
Administration: Impending Economic and Environmental Challenges, Mater. Chem. Horizons 2022 in press
10.22128/MCH.2022.588.1019.
[4] A. Moammeri, K. Abbaspour, A. Zafarian, E. Jamshidifar, H. Motasadizadeh, F. Dabbagh Moghaddam, Z. Salehi, P. Makvandi, R. Dinarvand, pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Breast Cancer, ACS applied bio materials 5(2) (2022) 675-690.
[5] P. Makvandi, R. Jamaledin, G. Chen, Z. Baghbantaraghdari, E.N. Zare, C. Di Natale, V. Onesto, R. Vecchione, J. Lee, F.R.
Tay, Stimuli-responsive transdermal microneedle patches, Materials Today 47 (2021) 206-222.
[6] Y. Liu, P. Lei, X. Liao, C. Wang, Nanoscale metal–organic frameworks as smart nanocarriers for cancer therapy, Journal of Nanostructure in Chemistry (2022) 1-19.
[7] N. Movagharnezhad, S. Ehsanimehr, P. Najafi Moghadam, Synthesis of Poly (N-vinylpyrrolidone)-grafted-Magnetite
Bromoacetylated Cellulose via ATRP for Drug Delivery, Materials Chemistry Horizons 1(2) (2022) 89-98.
[8] X. Hu, K. Saravanakumar, A. Sathiyaseelan, V. Rajamanickam, M.-H. Wang, Cytotoxicity of aptamer-conjugated chitosan encapsulated mycogenic gold nanoparticles in human lung cancer cells, Journal of Nanostructure in Chemistry (2021) 1-13.
[9] F. Dabbagh Moghaddam, F. Romana Bertani, Application of Microfluidic Platforms in Cancer Therapy, Materials Chemistry Horizons 1(1) (2022) 69-88.
[10] Y.-F. Sun, W. Guo, Y. Xu, Y.-H. Shi, Z.-J. Gong, Y. Ji, M. Du, X. Zhang, B. Hu, A.J.C.C.R. Huang, Circulating tumor cells
from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical
significance in hepatocellular carcinoma, 24(3) (2018) 547-559.
[11] X.H. Gao, L. Tian, J. Wu, X.L. Ma, C.Y. Zhang, Y. Zhou, Y.F. Sun, B. Hu, S.j. Qiu, J.J.H.R. Zhou, Circulating CD14+ HLA‐
DR-/low myeloid‐derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery, 47(10) (2017) 1061-1071.
[12] M. Aquib, M.A. Farooq, P. Banerjee, F. Akhtar, M.S. Filli, K.O. Boakye‐Yiadom, S. Kesse, F. Raza, M.B. Maviah, R.
Mavlyanova, Targeted and stimuli–responsive mesoporous silica nanoparticles for drug delivery and theranostic use, Journal of Biomedical Materials Research Part A 107(12) (2019) 2643-2666.
[13] S. Gulla, D. Lomada, P.B. Araveti, A. Srivastava, M.K. Murikinati, K.R. Reddy, M.C. Reddy, T. Altalhi, Titanium dioxide
nanotubes conjugated with quercetin function as an effective anticancer agent by inducing apoptosis in melanoma cells, Journal of Nanostructure in Chemistry 11(4) (2021) 721-734.
[14] K. Asifullah, Z. Zhou, W. He, K. Gao, M.W. Khan, R. Faisal, H. Muhammad, M. Sun, CXCR4-Receptor-Targeted Liposomes
for the Treatment of Peritoneal Fibrosis, Molecular pharmaceutics 16(6) (2019) 2728-2741.
[15] F. Raza, H. Zafar, X. You, A. Khan, J. Wu, L. Ge, Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers, Journal of Materials Chemistry B 7(48) (2019) 7639-7655.
[16] F. Raza, Y. Zhu, L. Chen, X. You, J. Zhang, A. Khan, M.W. Khan, M. Hasnat, H. Zafar, J. Wu, Paclitaxel-loaded pH responsive hydrogel based on self-assembled peptides for tumor targeting, Biomaterials science 7(5) (2019) 2023-2036.
[17] H. Zafar, M.H. Kiani, F. Raza, A. Rauf, I. Chaudhery, N.M. Ahmad, S. Akhtar, G. Shahnaz, Design of enzyme decorated
mucopermeating nanocarriers for eradication of H. pylori infection, Journal of Nanoparticle Research 22(1) (2020) 1-21.
[18] Y. Zhu, L. Wang, Y. Li, Z. Huang, S. Luo, Y. He, H. Han, F. Raza, J. Wu, L. Ge, Injectable pH and redox dual responsive
hydrogel based on self-assembled peptides for anti-tumor drug delivery, Biomaterials science 8 (2020) 5415-5426.
[19] C.-M.J. Hu, R.H. Fang, K.-C. Wang, B.T. Luk, S. Thamphiwatana, D. Dehaini, P. Nguyen, P. Angsantikul, C.H. Wen,
A.V.J.N. Kroll, Nanoparticle biointerfacing by platelet membrane cloaking, 526(7571) (2015) 118-121.
[20] L. Rao, Q.F. Meng, Q. Huang, Z. Wang, G.T. Yu, A. Li, W. Ma, N. Zhang, S.S. Guo, X.Z.J.A.F.M. Zhao, Platelet–leukocyte
hybrid membrane‐coated immunomagnetic beads for highly efficient and highly specific isolation of circulating tumor cells, 28(34) (2018) 1803531.
[21] H. Sun, J. Su, Q. Meng, Q. Yin, L. Chen, W. Gu, Z. Zhang, H. Yu, P. Zhang, S.J.A.F.M. Wang, Cancer cell membrane‐coated gold nanocages with hyperthermia‐triggered drug release and homotypic target inhibit growth and metastasis of breast cancer, 27(3) (2017) 1604300.
[22] Z. Cheng, S. Liu, X. Wu, F. Raza, Y. Li, W. Yuan, M. Qiu, J. Su, Autologous erythrocytes delivery of berberine hydrochloride with long-acting effect for hypolipidemia treatment, Drug delivery 27(1) (2020) 283-291.
[23] Y. Lian, X. Wang, P. Guo, Y. Li, F. Raza, J. Su, M. Qiu, Erythrocyte membrane-coated arsenic trioxide-loaded sodium alginate nanoparticles for tumor therapy, Pharmaceutics 12(1) (2020) 21.
[24] F. Raza, H. Zafar, S. Zhang, Z. Kamal, J. Su, W.E. Yuan, Q. Mingfeng, Recent Advances in Cell Membrane‐Derived
Biomimetic Nanotechnology for Cancer Immunotherapy, Advanced Healthcare Materials 10(6) (2021) 2002081.
[25] X. Wu, Y. Li, F. Raza, X. Wang, S. Zhang, R. Rong, M. Qiu, J. Su, Red Blood Cell Membrane-Camouflaged Tedizolid
Phosphate-Loaded PLGA Nanoparticles for Bacterial-Infection Therapy, Pharmaceutics 13(1) (2021) 99.
[26] E. Xu, X. Wu, X. Zhang, K. Zul, F. Raza, J. Su, M. Qiu, Study on the protection of dextran on erythrocytes during drug
loading, Colloids and Surfaces B: Biointerfaces 189 (2020) 110882.
[27] S.A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D.L. Porter, S.R. Rheingold, D.T. Teachey, A. Chew, B. Hauck, J.F.J.N.E.J.o.M.
Wright, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, 368(16) (2013) 1509-1518.
[28] R.J. Brentjens, I. Riviere, J.H. Park, M.L. Davila, X. Wang, J. Stefanski, C. Taylor, R. Yeh, S. Bartido, O.J.B. Borquez-Ojeda,
The Journal of the American Society of Hematology, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, 118(18) (2011) 4817-4828.
[29] J.N. Kochenderfer, M.E. Dudley, S.A. Feldman, W.H. Wilson, D.E. Spaner, I. Maric, M. Stetler-Stevenson, G.Q. Phan, M.S.
Hughes, R.M.J.B. Sherry, The Journal of the American Society of Hematology, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells, 119(12) (2012) 2709-2720.
[30] N. Ahmed, V.S. Brawley, M. Hegde, C. Robertson, A. Ghazi, C. Gerken, E. Liu, O. Dakhova, A. Ashoori, A.J.J.o.c.o. Corder, Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma, 33(15) (2015) 1688.
[31] S. Katz, G.R. Point, M. Cunetta, M. Thorn, P. Guha, N.J. Espat, C. Boutros, N. Hanna, R.P.J.C.g.t. Junghans, Regional CART cell infusions for peritoneal carcinomatosis are superior to systemic delivery, 23(5) (2016) 142-148.
[32] K. Feng, Y. Guo, H. Dai, Y. Wang, X. Li, H. Jia, W.J.S.C.l.s. Han, Chimeric antigen receptor-modified T cells for the
immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer, 59(5) (2016) 468- 479.
[33] T.T.B. Ho, A. Nasti, A. Seki, T. Komura, H. Inui, T. Kozaka, Y. Kitamura, K. Shiba, T. Yamashita, T. Yamashita, E.
Mizukoshi, K. Kawaguchi, T. Wada, M. Honda, S. Kaneko, Y. Sakai, Combination of gemcitabine and anti-PD-1 antibody
enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis, Journal for immunotherapy of cancer 8(2) (2020).
[34] I.R.J.J.o.a. Cohen, Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: a
comprehensive review, 54 (2014) 112-117.
[35] B.V. Kumar, T.J. Connors, D.L.J.I. Farber, Human T cell development, localization, and function throughout life, 48(2) (2018) 202-213.
[36] R.A. Clark, T.S.J.B. Kupper, IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from
human skin, 109(1) (2007) 194-202.
[37] E.J. Moticka, Chapter 27 - T-Lymphocyte-Mediated Effector Mechanisms, in: E.J. Moticka (Ed.), A Historical Perspective on Evidence-Based Immunology, Elsevier, Amsterdam, 2016, pp. 235-242.
[38] J.J. Thome, N. Yudanin, Y. Ohmura, M. Kubota, B. Grinshpun, T. Sathaliyawala, T. Kato, H. Lerner, Y. Shen, D.L.J.C. Farber, Spatial map of human T cell compartmentalization and maintenance over decades of life, 159(4) (2014) 814-828.
[39] N.A. Young, T. Al-Saleem, CHAPTER 24 - Lymph Nodes: Cytomorphology and Flow Cytometry, in: M. Bibbo, D. Wilbur
(Eds.), Comprehensive Cytopathology (Third Edition), W.B. Saunders, Edinburgh, 2008, pp. 671-711.
[40] J.H. Krouse, Chapter 1 - Introduction to Allergy, in: J.H. Krouse, M.J. Derebery, S.J. Chadwick (Eds.), Managing the Allergic Patient, W.B. Saunders, Edinburgh, 2008, pp. 1-17.
[41] C.M. Mousset, W. Hobo, R. Woestenenk, F. Preijers, H. Dolstra, A.B. van der Waart, Comprehensive phenotyping of T cells using flow cytometry, Cytometry Part A 95(6) (2019) 647-654.
[42] S.S. Shobeiri, M. MohammadniaAfrouzi, N. Jafari, S. Abediankenari, Regulatory T Cells: Types, Generation and Function, Journal of Mazandaran University of Medical Sciences 24(117) (2014) 225-246.
[43] A.D. Fesnak, C.H. June, B.L. Levine, Engineered T cells: the promise and challenges of cancer immunotherapy, Nature
reviews cancer 16(9) (2016) 566-581.
[44] M. Chmielewski, H. Abken, TRUCKs: the fourth generation of CARs, Expert opinion on biological therapy 15(8) (2015)
1145-1154.
[45] J. Hartmann, M. Schüßler‐Lenz, A. Bondanza, C.J. Buchholz, Clinical development of CAR T cells—challenges and
opportunities in translating innovative treatment concepts, EMBO molecular medicine 9(9) (2017) 1183-1197.
[46] K. Tsougeni, G. Papadakis, M. Gianneli, A. Grammoustianou, V. Constantoudis, B. Dupuy, P. Petrou, S. Kakabakos, A.
Tserepi, E.J.L.o.a.C. Gizeli, Plasma nanotextured polymeric lab-on-a-chip for highly efficient bacteria capture and lysis, 16(1) (2016) 120-131.
[47] J.R. Buser, X. Zhang, S. Byrnes, P. Ladd, E. Heiniger, M. Wheeler, J. Bishop, J. Englund, B. Lutz, B.J.A.M. Weigl, A
disposable chemical heater and dry enzyme preparation for lysis and extraction of DNA and RNA from microorganisms, 8(14) (2016) 2880-2886.
[48] J. Reboud, Y. Bourquin, R. Wilson, G.S. Pall, M. Jiwaji, A.R. Pitt, A. Graham, A.P. Waters, J.M.J.P.o.t.N.A.o.S. Cooper,
Shaping acoustic fields as a toolset for microfluidic manipulations in diagnostic technologies, 109(38) (2012) 15162-15167.
[49] R.M. Taskova, H. Zorn, U. Krings, H. Bouws, R.G.J.Z.f.N.C. Berger, A comparison of cell wall disruption techniques for the isolation of intracellular metabolites from Pleurotus and Lepista sp, 61(5-6) (2006) 347-350.
[50] C.W. Ho, W.S. Tan, W.B. Yap, T.C. Ling, B.T.J.B. Tey, B. engineering, Comparative evaluation of different cell disruption
methods for the release of recombinant hepatitis B core antigen from Escherichia coli, 13(5) (2008) 577-583.
[51] L. Rao, B. Cai, L.-L. Bu, Q.-Q. Liao, S.-S. Guo, X.-Z. Zhao, W.-F. Dong, W.J.A.N. Liu, Microfluidic electroporationfacilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging-guided cancer therapy, 11(4) (2017) 3496-3505.
[52] A.K.A. Silva, R. Di Corato, T. Pellegrino, S. Chat, G. Pugliese, N. Luciani, F. Gazeau, C.J.N. Wilhelm, Cell-derived vesicles
as a bioplatform for the encapsulation of theranostic nanomaterials, 5(23) (2013) 11374-11384.
[53] B. Liu, W. Wang, J. Fan, Y. Long, F. Xiao, M. Daniyal, C. Tong, Q. Xie, Y. Jian, B. Li, X. Ma, W. Wang, RBC membrane
camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer, Biomaterials 217 (2019) 119301.
[54] Y. Zhai, J. Su, W. Ran, P. Zhang, Q. Yin, Z. Zhang, H. Yu, Y. Li, Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy, Theranostics 7 (2017) 2575-2592.
[55] Y. Zhang, K. Cai, C. Li, Q. Guo, Q. Chen, X. He, L. Liu, Y. Zhang, Y. Lu, X. Chen, T. Sun, Y. Huang, J. Cheng, C. Jiang,
Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy, Nano Letters 18(3) (2018) 1908-1915.
[56] H. Cao, Z. Dan, X. He, Z. Zhang, H. Yu, Q. Yin, Y. Li, Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer, ACS Nano 10(8) (2016) 7738-7748.
[57] M.G. Rudolph, R.L. Stanfield, I.A. Wilson, How TCRs bind MHCs, peptides, and coreceptors, Annu Rev Immunol 24 (2006) 419-66.
[58] P.G. Coulie, B.J. Van den Eynde, P. van der Bruggen, T. Boon, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy, Nat Rev Cancer 14(2) (2014) 135-46.
[59] Y. Zhu, J. Feijen, Z. Zhong, Dual-targeted nanomedicines for enhanced tumor treatment, Nano Today 18 (2018) 65-85.
[60] M. Chidambaram, R. Manavalan, K. Kathiresan, Nanotherapeutics to overcome conventional cancer chemotherapy
limitations, J Pharm Pharm Sci 14(1) (2011) 67-77.
[61] S. Yaman, H. Ramachandramoorthy, G. Oter, D. Zhukova, T. Nguyen, M.K. Sabnani, J.A. Weidanz, K.T. Nguyen, Melanoma Peptide MHC Specific TCR Expressing T-Cell Membrane Camouflaged PLGA Nanoparticles for Treatment of Melanoma Skin Cancer, Frontiers in bioengineering and biotechnology 8 (2020) 943.
[62] K. Esfahani, L. Roudaia, N. Buhlaiga, S.V. Del Rincon, N. Papneja, W.H. Miller, A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future, Current Oncology 2020, Vol. 27, Pages 87-97 27 (2020) 87-97.
[63] P. Gong, Y. Wang, P. Zhang, Z. Yang, W. Deng, Z. Sun, M. Yang, X. Li, G. Ma, G. Deng, S. Dong, L. Cai, W. Jiang,
Immunocyte membrane-coated nanoparticles for cancer immunotherapy, Cancers 13 (2021) 1-17.
[64] M. Kang, J. Hong, M. Jung, S.P. Kwon, S.Y. Song, H.Y. Kim, J.R. Lee, S. Kang, J. Han, J.H. Koo, J.H. Ryu, S. Lim, H.S.
Sohn, J.M. Choi, J. Doh, B.S. Kim, T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy, Advanced Materials 32
(2020).
[65] L. Rao, S.K. Zhao, C. Wen, R. Tian, L. Lin, B. Cai, Y. Sun, F. Kang, Z. Yang, L. He, J. Mu, Q.F. Meng, G. Yao, N. Xie, X.
Chen, Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles, Advanced Materials 32 (2020) 2004853.
[66] Y. Zhai, J. Wang, T. Lang, Y. Kong, R. Rong, Y. Cai, W. Ran, F. Xiong, C. Zheng, Y. Wang, Y. Yu, H.H. Zhu, P. Zhang, Y.
Li, T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy, Nat Nanotechnol 16(11) (2021) 1271-1280.
[67] Z. Yang, Z. Sun, Y. Ren, X. Chen, W. Zhang, X. Zhu, Z. Mao, J. Shen, S. Nie, Advances in nanomaterials for use in
photothermal and photodynamic therapeutics (Review), Molecular medicine reports 20(1) (2019) 5-15.
[68] S. Liao, W. Yue, S. Cai, Q. Tang, W. Lu, L. Huang, T. Qi, J. Liao, Improvement of Gold Nanorods in Photothermal Therapy: Recent Progress and Perspective, Front Pharmacol 12 (2021) 664123.
[69] W. Ma, D. Zhu, J. Li, X. Chen, W. Xie, X. Jiang, L. Wu, G. Wang, Y. Xiao, Z. Liu, F. Wang, A. Li, D. Shao, W. Dong, W.
Liu, Y. Yuan, Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment, Theranostics 10 (2020) 1281-1295.
[70] Y. Han, H. Pan, W. Li, Z. Chen, A. Ma, T. Yin, R. Liang, F. Chen, Y. Ma, Y. Jin, M. Zheng, B. Li, L. Cai, T Cell Membrane
Mimicking Nanoparticles with Bioorthogonal Targeting and Immune Recognition for Enhanced Photothermal Therapy,
Advanced Science 6 (2019) 1-9.
[71] K. Bhatia, Bhumika, A. Das, Combinatorial drug therapy in cancer - New insights, Life sciences 258 (2020) 118134.
[72] M.J. Eblan, A.Z. Wang, Improving chemoradiotherapy with nanoparticle therapeutics, Transl Cancer Res 2(4) (2013) 320- 329.
[73] L. Zhang, R. Li, H. Chen, J. Wei, H. Qian, S. Su, J. Shao, L. Wang, X. Qian, B. Liu, Human cytotoxic T-lymphocyte
membrane-camouflaged nanoparticles combined with low-dose irradiation: A new approach to enhance drug targeting in gastric cancer, International journal of nanomedicine, 2017, pp. 2129-2142.
[74] Y. Zhai, W. Ran, J. Su, T. Lang, J. Meng, G. Wang, P. Zhang, Y. Li, Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR-Trigged Intracellular Delivery of Methylene Blue and Cisplatin, Adv Mater (2018)
e1802378.
[75] R. Bagherifar, S.H. Kiaie, Z. Hatami, A. Ahmadi, A. Sadeghnejad, B. Baradaran, R. Jafari, Y. Javadzadeh, Nanoparticlemediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives, Journal of nanobiotechnology 19(1) (2021) 110.
[76] J. Liang, H. Wang, W. Ding, J. Huang, X. Zhou, H. Wang, X. Dong, G. Li, E. Chen, F. Zhou, H. Fan, J. Xia, B. Shen, D. Cai,
P. Lan, H. Jiang, J. Ling, Z. Cheng, X. Liu, J. Sun, Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity, Sci Adv 6(35) (2020) eabc3646.
[77] X. Li, W. Zhang, J. Lin, H. Wu, Y. Yao, J. Zhang, C. Yang, T cell membrane cloaking tumor microenvironment-responsive
nanoparticles with a smart "membrane escape mechanism" for enhanced immune-chemotherapy of melanoma, Biomater Sci 9(9) (2021) 3453-3464.
[78] F. Combes, E. Meyer, N.N.J.J.o.C.R. Sanders, Immune cells as tumor drug delivery vehicles, J. Control Release 10(2020)
70-87.
)
)